User login
Study of Bioengineered Vessels for Dialysis Vascular Access Promising
The idea of using bioengineered human acellular vessels for dialysis vascular access used to be a pie-in-the-sky notion, but research presented today will demonstrate just how close they are to becoming a realistic option.
Dr. Jeffrey H. Lawson will present results from two Phase II single-arm trials of bioengineered human acellular vessels for dialysis access in 60 patients with end-stage renal disease conducted in six hospitals: three in the United States and three in Poland. His presentation is entitled “Tissue Engineered Blood Vessels for Arterial Bypass and Dialysis Access: Midterm Results n Patients.” To date, the early clinical experience with these vessels “suggests that they are safe to implant as a dialysis access vessel and lower leg bypass graft,” said Dr. Lawson, chief medical officer at Humacyte and professor of surgery and pathology in the department of surgery at Duke University, Durham, N.C. “They enjoy enduring patency, tolerate needed interventions, appear durable and have a low risk of infection.”
The researchers observed that during 82 patient-years of follow-up, only one vessel became infected. The vessels had no dilatation and rarely had postcannulation bleeding. At 6 months, 63% of patients had primary patency, 73% had primary assisted patency, and 97% had secondary patency, with most loss of primary patency because of thrombosis. At 1 year, 28% had primary patency, 38% had primary assisted patency, and 89% had secondary patency. “Following implantation into patients, the human acellular vessel (HAV) appears to completely repopulate with the host’s (recipient’s) own vascular tissue,” Dr. Lawson said. “The vessel is filled with cells that look like vascular smooth muscle cells and the implanted vessel is lined with endothelial cells from the host, suggesting that the manufactured acellular vessel becomes repopulated with the hosts own cells making it part of their own body. I will also be discussing some unpublished work that we have done for lower leg arterial bypass work in 20 patients to date.”
Dr. Lawson acknowledged that the Phase II experience at a few clinical sites is a limitation of the current analysis. “These findings need to be confirmed and validated in a large Phase III clinical trial, which is now underway,” he said.
Session 60
“New Developments in Arterial Grafts; Stents and Stent-Grafts; Concepts and Techniques to Improve Their Use and Results”
Thursday, 1:54 p.m.– 3:24 p.m.
Grand Ballroom East, 3rd Floor
The idea of using bioengineered human acellular vessels for dialysis vascular access used to be a pie-in-the-sky notion, but research presented today will demonstrate just how close they are to becoming a realistic option.
Dr. Jeffrey H. Lawson will present results from two Phase II single-arm trials of bioengineered human acellular vessels for dialysis access in 60 patients with end-stage renal disease conducted in six hospitals: three in the United States and three in Poland. His presentation is entitled “Tissue Engineered Blood Vessels for Arterial Bypass and Dialysis Access: Midterm Results n Patients.” To date, the early clinical experience with these vessels “suggests that they are safe to implant as a dialysis access vessel and lower leg bypass graft,” said Dr. Lawson, chief medical officer at Humacyte and professor of surgery and pathology in the department of surgery at Duke University, Durham, N.C. “They enjoy enduring patency, tolerate needed interventions, appear durable and have a low risk of infection.”
The researchers observed that during 82 patient-years of follow-up, only one vessel became infected. The vessels had no dilatation and rarely had postcannulation bleeding. At 6 months, 63% of patients had primary patency, 73% had primary assisted patency, and 97% had secondary patency, with most loss of primary patency because of thrombosis. At 1 year, 28% had primary patency, 38% had primary assisted patency, and 89% had secondary patency. “Following implantation into patients, the human acellular vessel (HAV) appears to completely repopulate with the host’s (recipient’s) own vascular tissue,” Dr. Lawson said. “The vessel is filled with cells that look like vascular smooth muscle cells and the implanted vessel is lined with endothelial cells from the host, suggesting that the manufactured acellular vessel becomes repopulated with the hosts own cells making it part of their own body. I will also be discussing some unpublished work that we have done for lower leg arterial bypass work in 20 patients to date.”
Dr. Lawson acknowledged that the Phase II experience at a few clinical sites is a limitation of the current analysis. “These findings need to be confirmed and validated in a large Phase III clinical trial, which is now underway,” he said.
Session 60
“New Developments in Arterial Grafts; Stents and Stent-Grafts; Concepts and Techniques to Improve Their Use and Results”
Thursday, 1:54 p.m.– 3:24 p.m.
Grand Ballroom East, 3rd Floor
The idea of using bioengineered human acellular vessels for dialysis vascular access used to be a pie-in-the-sky notion, but research presented today will demonstrate just how close they are to becoming a realistic option.
Dr. Jeffrey H. Lawson will present results from two Phase II single-arm trials of bioengineered human acellular vessels for dialysis access in 60 patients with end-stage renal disease conducted in six hospitals: three in the United States and three in Poland. His presentation is entitled “Tissue Engineered Blood Vessels for Arterial Bypass and Dialysis Access: Midterm Results n Patients.” To date, the early clinical experience with these vessels “suggests that they are safe to implant as a dialysis access vessel and lower leg bypass graft,” said Dr. Lawson, chief medical officer at Humacyte and professor of surgery and pathology in the department of surgery at Duke University, Durham, N.C. “They enjoy enduring patency, tolerate needed interventions, appear durable and have a low risk of infection.”
The researchers observed that during 82 patient-years of follow-up, only one vessel became infected. The vessels had no dilatation and rarely had postcannulation bleeding. At 6 months, 63% of patients had primary patency, 73% had primary assisted patency, and 97% had secondary patency, with most loss of primary patency because of thrombosis. At 1 year, 28% had primary patency, 38% had primary assisted patency, and 89% had secondary patency. “Following implantation into patients, the human acellular vessel (HAV) appears to completely repopulate with the host’s (recipient’s) own vascular tissue,” Dr. Lawson said. “The vessel is filled with cells that look like vascular smooth muscle cells and the implanted vessel is lined with endothelial cells from the host, suggesting that the manufactured acellular vessel becomes repopulated with the hosts own cells making it part of their own body. I will also be discussing some unpublished work that we have done for lower leg arterial bypass work in 20 patients to date.”
Dr. Lawson acknowledged that the Phase II experience at a few clinical sites is a limitation of the current analysis. “These findings need to be confirmed and validated in a large Phase III clinical trial, which is now underway,” he said.
Session 60
“New Developments in Arterial Grafts; Stents and Stent-Grafts; Concepts and Techniques to Improve Their Use and Results”
Thursday, 1:54 p.m.– 3:24 p.m.
Grand Ballroom East, 3rd Floor
Session Tackles Merits and Shortcomings of Drug Coated Balloons
Most vascular surgeons have a preferred method for managing femoropopliteal lesions, but drug-coated balloons are emerging as a option for lower extremity lesions.
The Wednesday morning session, “More on Lower Extremity Occlusive Disease: New Developments in Drug Coated Balloons (DCBs); Dealing with Complex Lesions and Trials,” will feature opposing views on how to manage the most severe disease morphology.
In this important session, world renown experts also will discuss the current status and immediate future of drug-coated balloons (DCB) for use on the lower extremity.
“The treatment with DCB is a story of great success. In general, the patency rate is increased and this is with no side effects due to the coating,” said Dr. Gunnar Tepe of Rosenheim Hospital in Rosenheim, Germany. “In the near future treatment with uncoated balloons will be mainly replaced by DCBs.” Dr. Tepe will present a paper on the current status and future prospects of DCBs.
Understanding important technical aspects remains essential to successful outcomes with DCBs, according to Dr. Tepe. “We have to know that treatment with DCBs is not a stand-alone therapy which can be successful in all lesions,” said Dr. Tepe. “If DCBs fail to obtain long-term patency, it is either due to recoil or drug uptake. For recoil, the combination of DCBs and stents is perfect, but for better drug uptake vessel, preparation is needed.”
Dr. Tepe and others will offer a detailed analysis of the potential shortcomings of DCBs, such as in long lesions, and in calcified arteries, and how to overcome them.
“The future of DCBs for use in patients with the potential threat of amputation is under development internationally,” said Dr. Schneider. “Practitioners will leave the session fully updated on the latest data and analysis of the value of DCBs in daily practice, since the most current results from randomized trials, and large registry datasets from the United States and around the world will be presented side by side.”
The presentations include the 3-year results from the international, randomized, controlled IN.PACT SFA Trial that compared the IN.PACT DCB against standard angioplasty. On hand to analyze and discuss the results will be co-principal investigators Dr. Schneider, Dr. Tepe, as well as panelist Dr. John R. Laird of the Vascular Center at the University of California, Davis. Co-moderator and study investigator Dr. Dierk Scheinert, MD, of the Leipzig University Hospital in Germany, will also join the discussion.
“I believe the data will show that DCBs have significantly changed how we practice and that by using them when possible, we can substantially improve what we can offer to patients in terms of long-term durability of the reconstructions we perform for their blocked and damaged arteries,” Dr. Tepe said.
The session will also cover second- and third-generation DCBs that are currently under development.
“As has been the tradition for many years, the VEITH planning committee has been able to bring together the world experts with the most important experience in these topics to educate, debate, inform the broader community,” said Dr. Schneider.
Session 26:
More on Lower Extremity Occlusive Disease: New Developments in Drug Coated Balloons (DCBs); Dealing with Complex Lesions and Trials
Wednesday 10:13 p.m. –12:00 p.m.
Grand Ballroom East, 3rd Floor
Most vascular surgeons have a preferred method for managing femoropopliteal lesions, but drug-coated balloons are emerging as a option for lower extremity lesions.
The Wednesday morning session, “More on Lower Extremity Occlusive Disease: New Developments in Drug Coated Balloons (DCBs); Dealing with Complex Lesions and Trials,” will feature opposing views on how to manage the most severe disease morphology.
In this important session, world renown experts also will discuss the current status and immediate future of drug-coated balloons (DCB) for use on the lower extremity.
“The treatment with DCB is a story of great success. In general, the patency rate is increased and this is with no side effects due to the coating,” said Dr. Gunnar Tepe of Rosenheim Hospital in Rosenheim, Germany. “In the near future treatment with uncoated balloons will be mainly replaced by DCBs.” Dr. Tepe will present a paper on the current status and future prospects of DCBs.
Understanding important technical aspects remains essential to successful outcomes with DCBs, according to Dr. Tepe. “We have to know that treatment with DCBs is not a stand-alone therapy which can be successful in all lesions,” said Dr. Tepe. “If DCBs fail to obtain long-term patency, it is either due to recoil or drug uptake. For recoil, the combination of DCBs and stents is perfect, but for better drug uptake vessel, preparation is needed.”
Dr. Tepe and others will offer a detailed analysis of the potential shortcomings of DCBs, such as in long lesions, and in calcified arteries, and how to overcome them.
“The future of DCBs for use in patients with the potential threat of amputation is under development internationally,” said Dr. Schneider. “Practitioners will leave the session fully updated on the latest data and analysis of the value of DCBs in daily practice, since the most current results from randomized trials, and large registry datasets from the United States and around the world will be presented side by side.”
The presentations include the 3-year results from the international, randomized, controlled IN.PACT SFA Trial that compared the IN.PACT DCB against standard angioplasty. On hand to analyze and discuss the results will be co-principal investigators Dr. Schneider, Dr. Tepe, as well as panelist Dr. John R. Laird of the Vascular Center at the University of California, Davis. Co-moderator and study investigator Dr. Dierk Scheinert, MD, of the Leipzig University Hospital in Germany, will also join the discussion.
“I believe the data will show that DCBs have significantly changed how we practice and that by using them when possible, we can substantially improve what we can offer to patients in terms of long-term durability of the reconstructions we perform for their blocked and damaged arteries,” Dr. Tepe said.
The session will also cover second- and third-generation DCBs that are currently under development.
“As has been the tradition for many years, the VEITH planning committee has been able to bring together the world experts with the most important experience in these topics to educate, debate, inform the broader community,” said Dr. Schneider.
Session 26:
More on Lower Extremity Occlusive Disease: New Developments in Drug Coated Balloons (DCBs); Dealing with Complex Lesions and Trials
Wednesday 10:13 p.m. –12:00 p.m.
Grand Ballroom East, 3rd Floor
Most vascular surgeons have a preferred method for managing femoropopliteal lesions, but drug-coated balloons are emerging as a option for lower extremity lesions.
The Wednesday morning session, “More on Lower Extremity Occlusive Disease: New Developments in Drug Coated Balloons (DCBs); Dealing with Complex Lesions and Trials,” will feature opposing views on how to manage the most severe disease morphology.
In this important session, world renown experts also will discuss the current status and immediate future of drug-coated balloons (DCB) for use on the lower extremity.
“The treatment with DCB is a story of great success. In general, the patency rate is increased and this is with no side effects due to the coating,” said Dr. Gunnar Tepe of Rosenheim Hospital in Rosenheim, Germany. “In the near future treatment with uncoated balloons will be mainly replaced by DCBs.” Dr. Tepe will present a paper on the current status and future prospects of DCBs.
Understanding important technical aspects remains essential to successful outcomes with DCBs, according to Dr. Tepe. “We have to know that treatment with DCBs is not a stand-alone therapy which can be successful in all lesions,” said Dr. Tepe. “If DCBs fail to obtain long-term patency, it is either due to recoil or drug uptake. For recoil, the combination of DCBs and stents is perfect, but for better drug uptake vessel, preparation is needed.”
Dr. Tepe and others will offer a detailed analysis of the potential shortcomings of DCBs, such as in long lesions, and in calcified arteries, and how to overcome them.
“The future of DCBs for use in patients with the potential threat of amputation is under development internationally,” said Dr. Schneider. “Practitioners will leave the session fully updated on the latest data and analysis of the value of DCBs in daily practice, since the most current results from randomized trials, and large registry datasets from the United States and around the world will be presented side by side.”
The presentations include the 3-year results from the international, randomized, controlled IN.PACT SFA Trial that compared the IN.PACT DCB against standard angioplasty. On hand to analyze and discuss the results will be co-principal investigators Dr. Schneider, Dr. Tepe, as well as panelist Dr. John R. Laird of the Vascular Center at the University of California, Davis. Co-moderator and study investigator Dr. Dierk Scheinert, MD, of the Leipzig University Hospital in Germany, will also join the discussion.
“I believe the data will show that DCBs have significantly changed how we practice and that by using them when possible, we can substantially improve what we can offer to patients in terms of long-term durability of the reconstructions we perform for their blocked and damaged arteries,” Dr. Tepe said.
The session will also cover second- and third-generation DCBs that are currently under development.
“As has been the tradition for many years, the VEITH planning committee has been able to bring together the world experts with the most important experience in these topics to educate, debate, inform the broader community,” said Dr. Schneider.
Session 26:
More on Lower Extremity Occlusive Disease: New Developments in Drug Coated Balloons (DCBs); Dealing with Complex Lesions and Trials
Wednesday 10:13 p.m. –12:00 p.m.
Grand Ballroom East, 3rd Floor
Remembering three giants in vascular surgery
This year the VEITHsymposium will be paying tribute to three influential vascular surgeons who are no longer with us: Dr. Allan Callow, Dr. Calvin Ernst, and Dr. John (Jack) Connolly.
Dr. Jerry Goldstone, MD, will have the honor of offering his thoughts on these extraordinary gentlemen during a session on Wednesday morning.
“I knew all three of these men quite well at various stages of my career,” Dr. Goldstone said.
Dr. Allan Callow, who died Dec. 22, 2015, at the age of 99, was considered a pioneer in vascular surgery. His contributions to vascular surgery include helping to perfect carotid endarterectomy.
He served in the U.S. Navy during World War II, retiring with the rank of rear admiral and was “an excellent speaker and had accumulated a very large personal experience with carotid artery disease which he was most recognized for as a clinician.”
Dr. Goldstone noted the different career path that this “great role model” followed.
“The most inspirational thing was his late-in-life switch to a basic science career,” Dr. Goldstone said. “Most of us in academics have our most intense basic research very early in our careers, but Allan’s late research career is inspiring and makes so much sense for a variety of reasons, not the least of which is it avoids the physical demands of clinical research.” Dr. Callow received an NIH RO1 grant at a time when contemporaries were retiring, Dr. Goldstone added.
Dr. Calvin Ernst “was probably best known as an educator, author and very dynamic Society of Vascular Surgery,” Dr. Goldstone said. “During his years on the SVS council, he was very actively involved in just about every activity that affected vascular surgery.”
Describing him as a “true Michigan guy” who was born in Detroit and attended the University of Michigan for undergraduate and medical school and stayed on for his surgery residency and then joined the faculty, Dr. Goldstone also remembered his accomplishments outside of SVS.
“Cal was a renowned surgeon and educator,” Dr. Goldstone recalled. “He was a prolific writer, authoring more than 300 papers and books, the best known probably being the first four editions of ‘Current Therapy in Vascular Surgery’ with Dr. James Stanley. ... He also served as the second co-editor of the Journal of Vascular Surgery and played a very important role in the early success of that journal.”
Dr. Ernst retired from practice in 2001 and died July 7, 2015 at the age of 81.
Dr. Goldstone noted that Dr. John (Jack) Connolly’s interests in cardiac and vascular surgery were broad and that he achieved world-wide fame for his presentations and lectures.
“He had a very prominent international influence and received countless invitations to speak abroad.”
He received fellowships were at the Royal College of Surgeons of England, Ireland and Edinburgh, as well as honorary membership in the Japan Vascular Society and the Vascular Surgical Society of Great Britain and Ireland. He also was honored by the University of California Irvine in 2012 when the institution established the John E. Connolly Endowed Chair in Surgery.
Dr. Goldstone remembered how “Jack” was “always a presence during my surgical training and career. Like Dr. Callow, he was still giving talks and writing papers well into his last years of life. He was very active internationally and was a vascular ambassador. He was charming, friendly, always willing to help younger surgeons and always had a genuine smile when he saw you.”
“For many,” Dr. Goldstone continued, “Jack will also be remembered for his friendship and unselfish support and mentoring.”
Dr. Connolly died Jan. 20, 2016, at the age of 92.
Session 34: Giants No Longer With Us: A Tribute To Allan Callow, Calvin Ernst And John (Jack) Connolly
Wednesday, 10:16 a.m. - 10:21 a.m.
Location: Grand Ballroom West, 3rd Floor
This year the VEITHsymposium will be paying tribute to three influential vascular surgeons who are no longer with us: Dr. Allan Callow, Dr. Calvin Ernst, and Dr. John (Jack) Connolly.
Dr. Jerry Goldstone, MD, will have the honor of offering his thoughts on these extraordinary gentlemen during a session on Wednesday morning.
“I knew all three of these men quite well at various stages of my career,” Dr. Goldstone said.
Dr. Allan Callow, who died Dec. 22, 2015, at the age of 99, was considered a pioneer in vascular surgery. His contributions to vascular surgery include helping to perfect carotid endarterectomy.
He served in the U.S. Navy during World War II, retiring with the rank of rear admiral and was “an excellent speaker and had accumulated a very large personal experience with carotid artery disease which he was most recognized for as a clinician.”
Dr. Goldstone noted the different career path that this “great role model” followed.
“The most inspirational thing was his late-in-life switch to a basic science career,” Dr. Goldstone said. “Most of us in academics have our most intense basic research very early in our careers, but Allan’s late research career is inspiring and makes so much sense for a variety of reasons, not the least of which is it avoids the physical demands of clinical research.” Dr. Callow received an NIH RO1 grant at a time when contemporaries were retiring, Dr. Goldstone added.
Dr. Calvin Ernst “was probably best known as an educator, author and very dynamic Society of Vascular Surgery,” Dr. Goldstone said. “During his years on the SVS council, he was very actively involved in just about every activity that affected vascular surgery.”
Describing him as a “true Michigan guy” who was born in Detroit and attended the University of Michigan for undergraduate and medical school and stayed on for his surgery residency and then joined the faculty, Dr. Goldstone also remembered his accomplishments outside of SVS.
“Cal was a renowned surgeon and educator,” Dr. Goldstone recalled. “He was a prolific writer, authoring more than 300 papers and books, the best known probably being the first four editions of ‘Current Therapy in Vascular Surgery’ with Dr. James Stanley. ... He also served as the second co-editor of the Journal of Vascular Surgery and played a very important role in the early success of that journal.”
Dr. Ernst retired from practice in 2001 and died July 7, 2015 at the age of 81.
Dr. Goldstone noted that Dr. John (Jack) Connolly’s interests in cardiac and vascular surgery were broad and that he achieved world-wide fame for his presentations and lectures.
“He had a very prominent international influence and received countless invitations to speak abroad.”
He received fellowships were at the Royal College of Surgeons of England, Ireland and Edinburgh, as well as honorary membership in the Japan Vascular Society and the Vascular Surgical Society of Great Britain and Ireland. He also was honored by the University of California Irvine in 2012 when the institution established the John E. Connolly Endowed Chair in Surgery.
Dr. Goldstone remembered how “Jack” was “always a presence during my surgical training and career. Like Dr. Callow, he was still giving talks and writing papers well into his last years of life. He was very active internationally and was a vascular ambassador. He was charming, friendly, always willing to help younger surgeons and always had a genuine smile when he saw you.”
“For many,” Dr. Goldstone continued, “Jack will also be remembered for his friendship and unselfish support and mentoring.”
Dr. Connolly died Jan. 20, 2016, at the age of 92.
Session 34: Giants No Longer With Us: A Tribute To Allan Callow, Calvin Ernst And John (Jack) Connolly
Wednesday, 10:16 a.m. - 10:21 a.m.
Location: Grand Ballroom West, 3rd Floor
This year the VEITHsymposium will be paying tribute to three influential vascular surgeons who are no longer with us: Dr. Allan Callow, Dr. Calvin Ernst, and Dr. John (Jack) Connolly.
Dr. Jerry Goldstone, MD, will have the honor of offering his thoughts on these extraordinary gentlemen during a session on Wednesday morning.
“I knew all three of these men quite well at various stages of my career,” Dr. Goldstone said.
Dr. Allan Callow, who died Dec. 22, 2015, at the age of 99, was considered a pioneer in vascular surgery. His contributions to vascular surgery include helping to perfect carotid endarterectomy.
He served in the U.S. Navy during World War II, retiring with the rank of rear admiral and was “an excellent speaker and had accumulated a very large personal experience with carotid artery disease which he was most recognized for as a clinician.”
Dr. Goldstone noted the different career path that this “great role model” followed.
“The most inspirational thing was his late-in-life switch to a basic science career,” Dr. Goldstone said. “Most of us in academics have our most intense basic research very early in our careers, but Allan’s late research career is inspiring and makes so much sense for a variety of reasons, not the least of which is it avoids the physical demands of clinical research.” Dr. Callow received an NIH RO1 grant at a time when contemporaries were retiring, Dr. Goldstone added.
Dr. Calvin Ernst “was probably best known as an educator, author and very dynamic Society of Vascular Surgery,” Dr. Goldstone said. “During his years on the SVS council, he was very actively involved in just about every activity that affected vascular surgery.”
Describing him as a “true Michigan guy” who was born in Detroit and attended the University of Michigan for undergraduate and medical school and stayed on for his surgery residency and then joined the faculty, Dr. Goldstone also remembered his accomplishments outside of SVS.
“Cal was a renowned surgeon and educator,” Dr. Goldstone recalled. “He was a prolific writer, authoring more than 300 papers and books, the best known probably being the first four editions of ‘Current Therapy in Vascular Surgery’ with Dr. James Stanley. ... He also served as the second co-editor of the Journal of Vascular Surgery and played a very important role in the early success of that journal.”
Dr. Ernst retired from practice in 2001 and died July 7, 2015 at the age of 81.
Dr. Goldstone noted that Dr. John (Jack) Connolly’s interests in cardiac and vascular surgery were broad and that he achieved world-wide fame for his presentations and lectures.
“He had a very prominent international influence and received countless invitations to speak abroad.”
He received fellowships were at the Royal College of Surgeons of England, Ireland and Edinburgh, as well as honorary membership in the Japan Vascular Society and the Vascular Surgical Society of Great Britain and Ireland. He also was honored by the University of California Irvine in 2012 when the institution established the John E. Connolly Endowed Chair in Surgery.
Dr. Goldstone remembered how “Jack” was “always a presence during my surgical training and career. Like Dr. Callow, he was still giving talks and writing papers well into his last years of life. He was very active internationally and was a vascular ambassador. He was charming, friendly, always willing to help younger surgeons and always had a genuine smile when he saw you.”
“For many,” Dr. Goldstone continued, “Jack will also be remembered for his friendship and unselfish support and mentoring.”
Dr. Connolly died Jan. 20, 2016, at the age of 92.
Session 34: Giants No Longer With Us: A Tribute To Allan Callow, Calvin Ernst And John (Jack) Connolly
Wednesday, 10:16 a.m. - 10:21 a.m.
Location: Grand Ballroom West, 3rd Floor
Welcome to the 2016 VEITHsymposium
Welcome to the 43rd annual Vascular & Endovascular, Issues, Techniques and Horizons Symposium (VEITHsymposium). This year’s program promises to be one of the best, most comprehensive, and most thought-provoking of any of our meetings. This year we celebrate our 43rd anniversary and have introduced several improvements.
Nearly 600 international clinician/educators have gathered to provide attendees with the latest topics and advances that are important to the global vascular community. These data span the breadth of vascular diseases, diagnostic procedures, medical treatments, interventional procedures and open surgical advances for treating vascular disease. As is the hallmark of the VEITHsymposium, the 5-day program will run from dawn to dusk daily and will be fully captured in our online library.
Top vascular experts from around the world will provide updates on the latest clinical trials and offer insight into the real-life application of the most recent data to close the gap between the current state of knowledge and actual clinical practice.
Controversial issues will be approached from multiple perspectives to ensure a balanced, unbiased exposure of topics and to provide audience members with the information they need to make informed choices in their own practices.
This year our meeting continues its increased emphasis on venous disease. Three full days of the meeting are developments in venous disease of all sorts and active endovascular treatments in this rapidly expanding area of opportunity.
Some of the program’s other hot topics will be the continuing controversies surrounding parallel grafts (chimneys, and snorkel and sandwich grafts); multilayer open stents versus fenestrated and branched endografts; new developments in carotid stenting; new developments in the treatment of aortic dissections; a day devoted to the management of arteriovenous malformations (AVMs); new developments in the endovascular treatment of lower-extremity ischemia, particularly below the knee; the latest developments in EVAR and TEVAR including experiences with a plethora of new endovascular grafts and devices that have appeared on the scene in the last year; and improvements in the medical treatment of vascular disease and vascular patients undergoing surgery and other interventions. Important issues to vascular specialists and outpatient vascular treatment will also be highlighted.
This year’s program will include a special session all-day Tuesday, focused in the morning on management options for pulmonary embolism led by Dr. Michael R. Jaff. The afternoon part of the day will focus on new developments in the management of acute and chronic large vein occlusion, and will be led by Dr. Kenneth Ouriel.
This year there will also be sessions devoted to crucial issues for vascular specialists including changing relationships with government and the FDA and how to survive under new reimbursement rules and regulations including Obamacare. Our physician/educators will also offer a glimpse into some new techniques and technologies that have been available overseas, but are just gaining approval in the United States, such as drug-eluting balloons and stents.
Attendees will notice some other exciting changes or additions to this year’s program. We have included a new Job Fair Program on Friday in the Americas Hall 1 on the 3rd floor. In addition, there will be more breaks in the schedule to encourage exploration of state-of-the-art technology, products, and services available in the Exhibit areas and Pavilions. The Exhibit Halls are crowded with displays and booths of particular interest to vascular surgeons and vascular specialists. The Pavilions and Exhibits also offer attendees the chance to meet faculty and to network with other attendees and industry partners. This is one place to learn more about exciting new technologies and developments in our field.
Other new additions to our meeting this year will be an exciting Abbott Pavilion in the Americas Hall as well as an expanded Innovations and Investment Summit which facilitates interaction between innovators, industry and investors. This non-CME Session will be held from 8 AM to 3 PM on Thursday, November 17th in the Gramercy Suites on the 2nd floor, and will be led by Kenneth Ouriel, Jean Bismuth and Chris Cheng.
Also new this year will be an expanded VEITHsymposium mobile app, provided courtesy of Cook Medical. Download the app for your iPhone, iPad or Android phone or tablet! Search the App Store (iPhone/iPad) or Google Play Store (Android) for “VEITHsymposium 2016” and install the app. You will be able to access the complete program, create your personal program, add your notes, view the location of sessions and exhibitors on the floor plan, and much more. After you have installed the app and opened it for the first time, you can continue to use it offline. To receive the latest updates and announcements, you will need to be connected to the internet.
In addition, there will be expanded Associate Faculty programs which will give younger and less well-known vascular specialists the opportunity to present their work at the podium with leading experts as session moderators.
Again this year, an Online Library will be available for a minimal fee of $75 for clinical meeting attendees and will include access to talks, slides, videos, and panels from the meeting. This Library will enable all attendees to see and hear key presentations they may miss because of the concurrent sessions or other reasons. This library will be available 10-14 days after the meeting. Attendees should note in their program talks they wish to hear but could not, and then revisit the missed talks on the Online Library which is indexed exactly to the program. The talks are also indexed in the Library by presenter, topic, or session. This Library is a great resource for study, research or review for any purpose.
On behalf of all the meeting Co-Chairmen and our entire staff, we greatly appreciate you coming to our meeting. We hope it is our best meeting ever and that you find it educational, most useful and exciting so that you return next year.
Welcome to the 43rd annual Vascular & Endovascular, Issues, Techniques and Horizons Symposium (VEITHsymposium). This year’s program promises to be one of the best, most comprehensive, and most thought-provoking of any of our meetings. This year we celebrate our 43rd anniversary and have introduced several improvements.
Nearly 600 international clinician/educators have gathered to provide attendees with the latest topics and advances that are important to the global vascular community. These data span the breadth of vascular diseases, diagnostic procedures, medical treatments, interventional procedures and open surgical advances for treating vascular disease. As is the hallmark of the VEITHsymposium, the 5-day program will run from dawn to dusk daily and will be fully captured in our online library.
Top vascular experts from around the world will provide updates on the latest clinical trials and offer insight into the real-life application of the most recent data to close the gap between the current state of knowledge and actual clinical practice.
Controversial issues will be approached from multiple perspectives to ensure a balanced, unbiased exposure of topics and to provide audience members with the information they need to make informed choices in their own practices.
This year our meeting continues its increased emphasis on venous disease. Three full days of the meeting are developments in venous disease of all sorts and active endovascular treatments in this rapidly expanding area of opportunity.
Some of the program’s other hot topics will be the continuing controversies surrounding parallel grafts (chimneys, and snorkel and sandwich grafts); multilayer open stents versus fenestrated and branched endografts; new developments in carotid stenting; new developments in the treatment of aortic dissections; a day devoted to the management of arteriovenous malformations (AVMs); new developments in the endovascular treatment of lower-extremity ischemia, particularly below the knee; the latest developments in EVAR and TEVAR including experiences with a plethora of new endovascular grafts and devices that have appeared on the scene in the last year; and improvements in the medical treatment of vascular disease and vascular patients undergoing surgery and other interventions. Important issues to vascular specialists and outpatient vascular treatment will also be highlighted.
This year’s program will include a special session all-day Tuesday, focused in the morning on management options for pulmonary embolism led by Dr. Michael R. Jaff. The afternoon part of the day will focus on new developments in the management of acute and chronic large vein occlusion, and will be led by Dr. Kenneth Ouriel.
This year there will also be sessions devoted to crucial issues for vascular specialists including changing relationships with government and the FDA and how to survive under new reimbursement rules and regulations including Obamacare. Our physician/educators will also offer a glimpse into some new techniques and technologies that have been available overseas, but are just gaining approval in the United States, such as drug-eluting balloons and stents.
Attendees will notice some other exciting changes or additions to this year’s program. We have included a new Job Fair Program on Friday in the Americas Hall 1 on the 3rd floor. In addition, there will be more breaks in the schedule to encourage exploration of state-of-the-art technology, products, and services available in the Exhibit areas and Pavilions. The Exhibit Halls are crowded with displays and booths of particular interest to vascular surgeons and vascular specialists. The Pavilions and Exhibits also offer attendees the chance to meet faculty and to network with other attendees and industry partners. This is one place to learn more about exciting new technologies and developments in our field.
Other new additions to our meeting this year will be an exciting Abbott Pavilion in the Americas Hall as well as an expanded Innovations and Investment Summit which facilitates interaction between innovators, industry and investors. This non-CME Session will be held from 8 AM to 3 PM on Thursday, November 17th in the Gramercy Suites on the 2nd floor, and will be led by Kenneth Ouriel, Jean Bismuth and Chris Cheng.
Also new this year will be an expanded VEITHsymposium mobile app, provided courtesy of Cook Medical. Download the app for your iPhone, iPad or Android phone or tablet! Search the App Store (iPhone/iPad) or Google Play Store (Android) for “VEITHsymposium 2016” and install the app. You will be able to access the complete program, create your personal program, add your notes, view the location of sessions and exhibitors on the floor plan, and much more. After you have installed the app and opened it for the first time, you can continue to use it offline. To receive the latest updates and announcements, you will need to be connected to the internet.
In addition, there will be expanded Associate Faculty programs which will give younger and less well-known vascular specialists the opportunity to present their work at the podium with leading experts as session moderators.
Again this year, an Online Library will be available for a minimal fee of $75 for clinical meeting attendees and will include access to talks, slides, videos, and panels from the meeting. This Library will enable all attendees to see and hear key presentations they may miss because of the concurrent sessions or other reasons. This library will be available 10-14 days after the meeting. Attendees should note in their program talks they wish to hear but could not, and then revisit the missed talks on the Online Library which is indexed exactly to the program. The talks are also indexed in the Library by presenter, topic, or session. This Library is a great resource for study, research or review for any purpose.
On behalf of all the meeting Co-Chairmen and our entire staff, we greatly appreciate you coming to our meeting. We hope it is our best meeting ever and that you find it educational, most useful and exciting so that you return next year.
Welcome to the 43rd annual Vascular & Endovascular, Issues, Techniques and Horizons Symposium (VEITHsymposium). This year’s program promises to be one of the best, most comprehensive, and most thought-provoking of any of our meetings. This year we celebrate our 43rd anniversary and have introduced several improvements.
Nearly 600 international clinician/educators have gathered to provide attendees with the latest topics and advances that are important to the global vascular community. These data span the breadth of vascular diseases, diagnostic procedures, medical treatments, interventional procedures and open surgical advances for treating vascular disease. As is the hallmark of the VEITHsymposium, the 5-day program will run from dawn to dusk daily and will be fully captured in our online library.
Top vascular experts from around the world will provide updates on the latest clinical trials and offer insight into the real-life application of the most recent data to close the gap between the current state of knowledge and actual clinical practice.
Controversial issues will be approached from multiple perspectives to ensure a balanced, unbiased exposure of topics and to provide audience members with the information they need to make informed choices in their own practices.
This year our meeting continues its increased emphasis on venous disease. Three full days of the meeting are developments in venous disease of all sorts and active endovascular treatments in this rapidly expanding area of opportunity.
Some of the program’s other hot topics will be the continuing controversies surrounding parallel grafts (chimneys, and snorkel and sandwich grafts); multilayer open stents versus fenestrated and branched endografts; new developments in carotid stenting; new developments in the treatment of aortic dissections; a day devoted to the management of arteriovenous malformations (AVMs); new developments in the endovascular treatment of lower-extremity ischemia, particularly below the knee; the latest developments in EVAR and TEVAR including experiences with a plethora of new endovascular grafts and devices that have appeared on the scene in the last year; and improvements in the medical treatment of vascular disease and vascular patients undergoing surgery and other interventions. Important issues to vascular specialists and outpatient vascular treatment will also be highlighted.
This year’s program will include a special session all-day Tuesday, focused in the morning on management options for pulmonary embolism led by Dr. Michael R. Jaff. The afternoon part of the day will focus on new developments in the management of acute and chronic large vein occlusion, and will be led by Dr. Kenneth Ouriel.
This year there will also be sessions devoted to crucial issues for vascular specialists including changing relationships with government and the FDA and how to survive under new reimbursement rules and regulations including Obamacare. Our physician/educators will also offer a glimpse into some new techniques and technologies that have been available overseas, but are just gaining approval in the United States, such as drug-eluting balloons and stents.
Attendees will notice some other exciting changes or additions to this year’s program. We have included a new Job Fair Program on Friday in the Americas Hall 1 on the 3rd floor. In addition, there will be more breaks in the schedule to encourage exploration of state-of-the-art technology, products, and services available in the Exhibit areas and Pavilions. The Exhibit Halls are crowded with displays and booths of particular interest to vascular surgeons and vascular specialists. The Pavilions and Exhibits also offer attendees the chance to meet faculty and to network with other attendees and industry partners. This is one place to learn more about exciting new technologies and developments in our field.
Other new additions to our meeting this year will be an exciting Abbott Pavilion in the Americas Hall as well as an expanded Innovations and Investment Summit which facilitates interaction between innovators, industry and investors. This non-CME Session will be held from 8 AM to 3 PM on Thursday, November 17th in the Gramercy Suites on the 2nd floor, and will be led by Kenneth Ouriel, Jean Bismuth and Chris Cheng.
Also new this year will be an expanded VEITHsymposium mobile app, provided courtesy of Cook Medical. Download the app for your iPhone, iPad or Android phone or tablet! Search the App Store (iPhone/iPad) or Google Play Store (Android) for “VEITHsymposium 2016” and install the app. You will be able to access the complete program, create your personal program, add your notes, view the location of sessions and exhibitors on the floor plan, and much more. After you have installed the app and opened it for the first time, you can continue to use it offline. To receive the latest updates and announcements, you will need to be connected to the internet.
In addition, there will be expanded Associate Faculty programs which will give younger and less well-known vascular specialists the opportunity to present their work at the podium with leading experts as session moderators.
Again this year, an Online Library will be available for a minimal fee of $75 for clinical meeting attendees and will include access to talks, slides, videos, and panels from the meeting. This Library will enable all attendees to see and hear key presentations they may miss because of the concurrent sessions or other reasons. This library will be available 10-14 days after the meeting. Attendees should note in their program talks they wish to hear but could not, and then revisit the missed talks on the Online Library which is indexed exactly to the program. The talks are also indexed in the Library by presenter, topic, or session. This Library is a great resource for study, research or review for any purpose.
On behalf of all the meeting Co-Chairmen and our entire staff, we greatly appreciate you coming to our meeting. We hope it is our best meeting ever and that you find it educational, most useful and exciting so that you return next year.